Inventor · disambiguated record
Yong Tang
Also filed as: TANG YONG · TANG YONG BIN
7 granted patents·5 pending applications·11 citations·filing 2013–2023
75Inventor score
Files withGENENTECH INC5RECLUDIX PHARMA INC3BEIJING DABEINONG TECH GROUP1RELAY THERAPEUTICS INC1SALUBRIS CHENGDU BIOTECH CO LTD1
Top patents by PatentIndex Score
12 records- 0187US10308614B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Jun 4, 2019·4 cites·21 claims
- 0285US11591336B2Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitorsRELAY THERAPEUTICS INC·Filed 2018·Granted Feb 28, 2023·3 cites·54 claims
- 0379US10183009B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Jan 22, 2019·3 cites·22 claims
- 0468US10150767B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Dec 11, 2018·1 cites·14 claims
- 0561US2025215030A1Stat modulators and uses thereofRECLUDIX PHARMA INC·Filed 2023·Application pending·0 cites
- 0660US2025215029A1Stat modulators and uses thereofRECLUDIX PHARMA INC·Filed 2023·Application pending·0 cites
- 0758US2025179103A16-oxodecahydropyrrolo[1,2-a][1,5]diazocine and 6-oxodecahydro-4h-pyrrolo[2,1-d][1,5]thiazocine derivatives as stat3 and stat6 modulators for the treatment of cancer and inflammatory conditionsRECLUDIX PHARMA INC·Filed 2023·Application pending·0 cites
- 0852US9873105B2Sorbent material and a method for enhancing sorption performance thereofUNIV CITY HONG KONG·Filed 2014·Granted Jan 23, 2018·0 cites·10 claims
- 0942US2021095032A1Antibodies binding pd-1 and uses thereofSALUBRIS CHENGDU BIOTECH CO LTD·Filed 2019·Application pending·0 cites
- 1040US10258603B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Apr 16, 2019·0 cites·15 claims
- 1140US10202378B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Feb 12, 2019·0 cites·18 claims
- 1240US2014165233A1Methods for pest controlBEIJING DABEINONG TECH GROUP·Filed 2013·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →